Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Prices $1B of Senior Notes

NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced after the close of the market on Monday that it has priced $1 billion of senior notes.

The Waltham, Massachusetts-based scientific products giant's 3 percent senior notes are paid on a semi-annual basis, and are due in 2023. The issue price is 99.512 percent of the principal amount.

The firm plans to use the proceeds, along with cash on hand, to redeem all of its outstanding $1 billion 2.25 percent senior notes that mature August 15. Thermo Fisher said it expects the issuance to close on or about April 13, subject to closing conditions.

Merrill Lynch, Pierce, Fenner & Smith, Goldman Sachs, and Morgan Stanley acted as joint book-running managers for the offering.

Fitch Ratings granted the senior notes a BBB rating with a Stable rating outlook on Monday.

In Tuesday morning trading on the New York Stock Exchange, shares of Thermo Fisher were trading down less than 1 percent at $142.79.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more